Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
- PMID: 26718855
- DOI: 10.1016/j.jconrel.2015.12.033
Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
Abstract
Monoclonal IgG antibodies (Abs) are used extensively in the clinic to treat cancer and autoimmune diseases. In addition, therapeutic proteins are genetically fused to the constant Fc part of IgG. In both cases, the Fc secures a long serum half-life and favourable pharmacokinetics due to its pH-dependent interaction with the neonatal Fc receptor (FcRn). FcRn also mediates transport of intact IgG across polarized epithelial barriers, a pathway that is attractive for delivery of Fc-containing therapeutics. So far, no study has thoroughly compared side-by-side how IgG and different Fc-fusion formats are transported across human polarizing epithelial cells. Here, we used an in vitro cellular transport assay based on the human polarizing epithelial cell line (T84) in which both IgG1 and Fc-fusions were transported in an FcRn-dependent manner. Furthermore, we found that the efficacy of transport was dependent on the format. We demonstrate that transepithelial delivery could be enhanced by Fc-engineering for improved FcRn binding as well as by Fc-polymerization. In both cases, transport was driven by pH-dependent binding kinetics and the pH at the luminal side. Hence, efficient transcellular delivery of IgG-based drugs across human epithelial cells requires optimal pH-dependent FcRn binding that can be manipulated by avidity and Fc-engineering, factors that should inspire the design of future therapeutics targeted for transmucosal delivery.
Keywords: Epithelial; Fc-fusion; FcRn; IgG; Mucosal barrier; Transcytosis; pH-dependent binding.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18. J Immunol. 2010. PMID: 20083659
-
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. J Drug Target. 2014. PMID: 24404896 Review.
-
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.MAbs. 2014 Mar-Apr;6(2):422-36. doi: 10.4161/mabs.27854. Epub 2014 Jan 15. MAbs. 2014. PMID: 24492301 Free PMC article.
-
Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells.Mol Biol Cell. 2008 Dec;19(12):5490-505. doi: 10.1091/mbc.e07-02-0101. Epub 2008 Oct 8. Mol Biol Cell. 2008. PMID: 18843053 Free PMC article.
-
Monoclonal Antibody Engineering and Design to Modulate FcRn Activities: A Comprehensive Review.Int J Mol Sci. 2022 Aug 24;23(17):9604. doi: 10.3390/ijms23179604. Int J Mol Sci. 2022. PMID: 36077002 Free PMC article. Review.
Cited by
-
Impact of Glycosylation and Species Origin on the Uptake and Permeation of IgGs through the Nasal Airway Mucosa.Pharmaceutics. 2020 Oct 23;12(11):1014. doi: 10.3390/pharmaceutics12111014. Pharmaceutics. 2020. PMID: 33114132 Free PMC article.
-
Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.MAbs. 2024 Jan-Dec;16(1):2361585. doi: 10.1080/19420862.2024.2361585. Epub 2024 Jun 7. MAbs. 2024. PMID: 38849969 Free PMC article.
-
Considerations for the Design of Antibody-Based Therapeutics.J Pharm Sci. 2020 Jan;109(1):74-103. doi: 10.1016/j.xphs.2019.05.031. Epub 2019 Jun 4. J Pharm Sci. 2020. PMID: 31173761 Free PMC article. Review.
-
Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus.J Immunol. 2019 Mar 1;202(5):1595-1611. doi: 10.4049/jimmunol.1801337. Epub 2019 Jan 25. J Immunol. 2019. PMID: 30683699 Free PMC article.
-
FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy?Int J Mol Sci. 2019 Mar 19;20(6):1379. doi: 10.3390/ijms20061379. Int J Mol Sci. 2019. PMID: 30893823 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources